Joseph Masdeau, M.D., Ph.D.<\/a>, director of the Nantz National Alzheimer Center at Houston Methodist, called Racing to End Alzheimer\u2019s mission \u201cextremely rewarding\u201d for researchers, patients and their families.<\/p>\n\u201c[Frengs] is not only raising funds, but he\u2019s raising awareness of this disease and doing it in a very optimistic way,\u201d he said. \u201cThat\u2019s something very nice to see\u2014to see that someone is going out and showing that this is something that involves many of us and there is a future with hope for people with this disease.\u201d<\/p>\n
Since the foundation\u2019s inception, Frengs has helped Masdeau pursue cutting-edge research at the Nantz Center in an effort to find an effective treatment for the disease. Currently, medications approved by the U.S. Food and Drug Administration (FDA) only treat the symptoms, not the disease.<\/p>\n
\u201c[The disease] continues to worsen, but the only thing the medications do is change the symptoms,\u201d Masdeau said. \u201cThey don\u2019t change the underlying pathological process.\u201d<\/p>\n
The field of Alzheimer\u2019s research has been historically riddled with disappointment and desperately needs a win. Despite a spate of failed clinical trials, more advanced imaging technology developed over the past few years\u2014such as positron emission tomography (PET) imaging of amyloids, tau and inflammation\u2014is one of the main exciting sea changes in Alzheimer\u2019s research. Highly detailed imaging allows scientists to look inside the brain and understand exactly what is going on in a specific patient \u201cso that we are beginning to tailor the treatment to what is going on in the person\u2019s brain rather than generally,\u201d Masdeau said.<\/p>\n
\u201cWe\u2019re finding out that Alzheimer\u2019s is very heterogeneous,\u201d he further explained. \u201cIt behaves very differently in people. It is likely that it is different in different individuals and that\u2019s why they respond differently. That\u2019s probably why many of the clinical trials that have been performed in the past have been negative because we\u2019re mixing apples and oranges and bananas.\u201d<\/p>\n
But there is a price for progress. Federal grants from agencies, such as the National Institutes of Health (NIH), don\u2019t cover everything\u2014making philanthropic initiatives, such as Frengs\u2019 foundation, \u201cabsolutely critical for innovative research,\u201d Masdeau said.<\/p>\n
\u201cGrants from agencies, like the NIH, tend to avoid interventions or approaches that are very novel [because they\u2019re] risky in the sense because they\u2019re new and we don\u2019t have enough data to support them,\u201d Masdeau explained. \u201cYou cannot move along the lines of very novel approaches with NIH funding.\u201d<\/p>\n
This year, Frengs presented Masdeau with a check for $78,632. To date, the foundation has raised nearly $280,000.<\/p>\n
\u201cIt\u2019s going to add up over time and it\u2019s going to make a difference in each of these organizations,\u201d Frengs said. \u201cAs a businessman and entrepreneur, I\u2019m part of the group of people who thinks that we can always fix something. Just give me a problem and I\u2019ll fix it. The truth of the matter is, when it comes to Alzheimer\u2019s, there isn\u2019t much you can do. For me, this foundation\u2014this effort to raise awareness around Alzheimer\u2019s and dementia\u2014is something I can do.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
Racing to End Alzheimer’s race car stops by Houston Methodist to raise money and awareness <\/p>\n","protected":false},"author":15,"featured_media":31626,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[920,4794,2593,4795,4793,4792,4525,4791,4796,4790],"yoast_head":"\n
Racing to fund the cure and the care for Alzheimer's disease - TMC News<\/title>\n \n \n \n \n \n \n \n \n \n \n \n \n\t \n\t \n\t \n \n \n \n\t \n\t \n\t \n